INTRODUCTION
IgG4-related disease (IgG4-RD) is a chronic fibroinflammatory condition characterized by tumefactive lesions, dense lymphoplasmacytic infiltrates, and abundant IgG4-bearing plasma cells in the affected tissues. Serum IgG4 concentrations in patients' sera are often elevated dramatically, yet are normal in approximately one-third of patients with clinicopathologically confirmed disease. IgG4-RD was described first in the pancreas -the condition once termed 'lymphoplasmacytic sclerosing pancreatitis' or sometimes just 'sclerosing pancreatitis', among other designations [1] .
Common histological features are now known to characterize IgG4-RD in essentially every organ in the body [2] . Broader experience with this condition, however, has led to the recognition that the diagnosis is critically dependent upon careful correlation between clinical, pathological, and often radiological findings. American College of Rheumatology/European League Against Rheumatism Classification Criteria are now being developed on the basis of this recognition.
The immunopathogenesis of IgG4-RD remains incompletely defined. B cells at first and subsequently T cells have been recognized to be key players in disease pathogenesis, but their full contributions to IgG4-RD remain to be elucidated. Moreover, other elements of the immune system are also likely to play important roles. Treatment of IgG4-RD to date has been predicated primarily on glucocorticoids, but the growing recognition of this approach's shortcomings has spawned earlier consideration of either nonspecific 'disease-modifying' agents or targeted treatments, both of which are intended as steroid-sparing strategies.
ROLE OF B CELLS
A first reliable advance into the pathophysiology of IgG4-RD was made when preliminary studies with rituximab (RTX) showed that B-cell depletion & ]. Clinical improvement was accompanied by a reduction in serum IgG4 levels. Further studies in IgG4-RD patients with active, untreated disease identified an oligoclonally expanded population of circulating CD19
þ bright plasmablasts (cells that are the precursors of tissue-resident, antibody-producing plasma cells). Flow cytometry studies following treatment demonstrated that clinical improvement correlated with selective depletion of this B-cell subpopulation [4 && ]. Many patients achieved clinical remissions without normalizing their serum IgG4 concentrations, even though substantial declines in serum IgG4 levels following treatment were the rule.
The B-cell compartment of patients with IgG4-RD has been studied extensively because the striking serum IgG4 elevation in many patients and the abundance of IgG4þ plasma cells at sites of disease initially suggested the possibility of an underlying lymphoproliferative condition. The latter hypothesis has then been excluded because of failure to identify monoclonal plasma cells populations in the affected tissues [2] , but the issue of a potential relationship between malignancy and IgG4-RD risk -and vice versa -remains an important topic.
At least two lines of evidence from the humoral immune system have suggested that an antigendriven immune response is present in IgG4-RD. Studies on the cerebrospinal fluid of patients with IgG4-related pachymeningitis revealed the presence of oligoclonal IgG4 [5] . In addition, next-generation sequencing analysis on tissue biopsy samples and on the peripheral blood of IgG4-RD patients demonstrated oligoclonal expansions of somatically hypermutated IgG4 þ B-cell clones [4 && ]. The oligoclonally expanded B cells were identified by flow cytometry as being CD19
þ plasmablasts. Plasmablasts arise in germinal centers following affinity maturation from naïve CD20þ precursors. Once in the bloodstream, plasmablasts differentiate into antibody-secreting short-lived or long-lived plasma cells, accounting for the excess IgG4 production in this disease [6] . Plasmablast concentrations in the blood correlate well with disease activity, decreasing sharply after RTX-induced remission and reemerging during relapse. It is worth noting that the plasmablasts reemerging during disease relapses express distinct V-J repertoires compared with samples from the same patients before their initial treatment. This phenomenon, known as 'clonal divergence', further supports the hypothesis of hypermutation driven by the selection of specific antigens.
ROLE OF T CELLS
T-cell responses have long been considered to be central to the pathophysiology of IgG4-RD, but the focus of interest within the T-cell population has shifted within recent years. Th2 immune responses were once believed critical to IgG4-RD pathways, partly because of the high frequency of atopic symptoms observed in many patients with IgG4-RD [7] and partly because of the detection of mRNA from cytokines frequently linked to Th2 responses, for example, IL-4, IL-5, and IL-13 [8] . More recent studies, however, have demonstrated expansions of Th2 cells only in the circulation of IgG4-RD patients with an atopic history, not in those without histories of atopy [9 & ]. It seems, therefore, that despite initial appearances, the role of Th2 cells in IgG4-RD is marginal. Other subpopulations of T cells, however, are involved more directly in IgG4-RD pathogenesis.
A novel population of effector memory CD4þ T cells with cytotoxic function [CD4þ cytotoxic T lymphocytes (CTLs)] has then been described in IgG4-RD patients [10 && ]. Substantial evidence suggests that this population of cells plays an important role in the pathophysiology of this disease. CD4þ CTLs are expanded in both the peripheral blood and in affected organs of IgG4-RD patients. Moreover, together with circulating plasmablasts (though at a slower rate), these CD4þ CTLs decline following RTX treatment, supporting the
KEY POINTS
Oligoclonal expansions of cells of both the B and T lymphocyte lineages are present in the blood of patients with IgG4-RD.
Blood plasmablast concentrations correlate well with disease activity -better even than do serum IgG4 levels.
An oligoclonally expanded population of CD4þ CTLs, found not only in the peripheral blood but also at tissue sites of active disease, elaborates cytokines that may drive the fibrosis characteristic of IgG4-RD.
Tfhc2 appears to play a major role in driving the IgG4 class switch.
Data from a recent study suggest that a history of malignancy may be a risk factor for IgG4-RD rather than vice versa.
The completion of classification criteria for IgG4-RD, an effort supported jointly by the American College of Rheumatology and the European League Against Rheumatism, will further facilitate studies on this disease.
concept that cells of the B-cell and T-cell lineages cooperate closely in mediating this condition [10 && ]. Cytotoxicity associated with CD4þ T-helper lymphocytes is a concept that has emerged progressively in the past few years. The concept contrasts with the traditional view that cytotoxic T cells arise only from major histocompatibility complex (MHC) class I-restricted CD8þ T lymphocytes. During thymic development, lineage commitment toward CD4þ or CD8þ T-cell fate is driven by the action and counteraction of the key transcription factors, ThPOK and Runx3, respectively [11] . CD4þ CTLs seem to represent highly differentiated, antigenexperienced (memory) T cells with features of both CD4þ and CD8þ T lymphocytes (though there are CD8À) [12] . It is likely that this cell population arises from chronic antigenic stimulation. Indeed, in response to repeated antigenic stimulation, ThPOK is downregulated, resulting in a cytolytic gene expression program in activated CD4þ T cells, with differentiation into MHC class II-restricted CD4þ CTLs and an effector cell phenotype [11] .
The CD4þ CTLs identified express high levels of CD11a and CD11b integrins, and CD45 isoform-RO and isoform-RB. They lack the costimulatory receptors CD27, CD28, the chemokine receptor CCR7, and CD45-RA. Small numbers of CD4þ CTLs can be detected in the blood of healthy individuals [13] , and they significantly increase during chronic viral infections (such as cytomegalovirus [14] , EpsteinBarr virus [15] , and HIV [13] ), malignancies [16] , and autoimmune disorders [17] . CD4þ CTLs seem to bear protective functions such as control of infected cells or elimination of transformed cells, thanks to their cytolytic MHC class II-restricted action. Nevertheless, the accumulation of CD4þ CTLs in the setting of autoimmune conditions such as rheumatoid arthritis [18] and inflammatory bowel disease [19] suggests that these cells might also contribute to chronic inflammation. Indeed, CD4þ CTLs numbers correlate with disease severity in rheumatoid arthritis and ankylosing spondylitis, and decrease after treatment with anti-TNFalpha agents [20] .
In summary, the CD4þ CTLs identified in the context of IgG4-RD represent the most carefully phenotyped such cell studied to date. The cell appears to have significant potential to contribute to chronic inflammation of a variety of forms.
ROLE OF T FOLLICULAR HELPER CELLS
The powerful evidence of class-switching in IgG4-RD has led to substantial interest in the role of T follicular helper (Tfh) cells in this condition. Tfh cells are known to be involved in the differentiation of B cells during their development and to contribute significantly to class switching [21] . Akiyama et al. [22, 23 && ] have reported that among Tfh cells subsets, Tfh2 cells induce the differentiation of naïve B cells into plasmablasts, subsequently promoting the production of IgG4 in active, untreated IgG4-RD. Circulating Tfh2 cells are expanded IgG4-RD and their concentrations are linked to disease activity, the concentrations of circulating plasmablasts, and serum IgG4 levels.
In contrast, although circulating activated Tfh1 cells were also found to be expanded in IgG4-RD, their levels correlated with disease activity but not with serum IgG4 levels. These findings support the hypothesis of a greater role for Tfh2 cells in the class switch observed in IgG4-RD. It is known that Tfh cells in germinal centers cooperate with B cells in the formation and antibody production. Therapy with glucocorticoids did not affect Tfh2 cell counts, but did result in a decrease in numbers of plasmablasts and levels of serum IgG4 and IL-4. As IL-4 is believed to be produced by Tfh2 cells and not by the other Tfh cell subsets, it is possible that glucocorticoid treatment affects the function and not the number of these cells.
PLASMACYTOID DENDRITIC CELLS
Plasmacytoid dendritic cells (pDCs) were shown to be important in the development of pancreatic inflammation through production of IFN-alpha [24 && ]. Autoimmune pancreatitis (AIP) in IgG4-RD patients is associated with an infiltration of pDCs. Peripheral pDCs from IgG4-RD patients were shown to enhance IgG4 antibody production by cells through IFN-alpha-mediated signaling. Demonstration of a role for IFN-alpha in this disease comes from studies conducted on experimental AIP models in which regression of the inflammation was seen to occur with depletion of IFN-alpha production or signaling.
Final proof of its relevance in AIP in humans requires studies with pDC-depleting antibodies or neutralizing IFN-alpha receptor antibodies. In addition to pDCs, inflamed pancreata also harbor NETs. These structures have been seen to be involved in the activation of pDCs [25] [26] . In fact, cocultures of pDCs and neutrophils, forced to express NETs by monosodium urate (MSU) crystals or antilactoferrin antibodies (NET component protein), showed increased production of IFN-alpha and the B lymphocyte-activating factor known as BAFF. Moreover, when these cells were cocultured together with B cells, they led to increases in IgG4 production.
Some data do support the notion that antilactoferrin antibodies contribute to IgG4-RD. Serum antilactoferrin antibody titers, especially those of the IgG4 subclass, were elevated in the serum of IgG4-RD patients. In contrast, there has to date been no demonstration of MSU deposition in the IgG4-related pancreatic lesion.
THERAPY
A group of international experts published a Consensus Guidance Statement on the Management of IgG4-RD [27] . This effort grew out of the Second International Symposium on IgG4-RD and Associated Conditions, held in 2014. The Third such Symposium is scheduled for 2017, and it is there that the ACR/EULAR Classification Criteria will be completed.
RTX was used initially in patients who did not respond to glucocorticoids, conventional steroidsparing agents, or both, under the assumption that B-cell depletion might ameliorate the condition through decreasing serum IgG4 concentrations [28] . The fundamental assumption underlying this approach now seems not entirely true. Indeed, careful mechanistic studies of patients with IgG4-RD treated with RTX have led to novel insights about the pathophysiology of this disorder. First, B-cell depletion targets the subset of plasma cells that produce IgG4 in IgG4-RD [29] , by depleting all circulating CD20À positive B cells, the precursors of short-lived plasma cells. Second, IgG4þ plasmablasts (CD38þCD27þCD19þCD20ÀIgG4þ cells) seem to be a good biomarker for IgG4-RD and are superior to serum IgG4 concentrations for diagnosis and monitoring of disease activity [30 & ].
Yamamoto et al. [31] described the use of abatacept (cytotoxic T lymphocytes-associated protein 4-immunoglobulin) to treat one patient with IgG4-RD whose condition had been refractory to RTX. Given the recognition of the importance of T cells in this disease now emerging, greater attention to treatment strategies directly targeting T-cell function may be of value.
TUMOR ASSOCIATION
Discussions of a possible link between IgG4-RD and malignancy have emerged recently. Evidence against such a relationship, however, came from a retrospective study showed that history of malignancy was 2.5 times more likely in IgG4-RD patients compared with the general US population [32 & ]. Moreover, a history of malignancy was three times more common among IgG4-RD patients than among control patients in a case-control analysis performed as part of the same study. Prostate cancer was the most common malignancy in both the IgG4-RD patients and the controls, a point not surprising given the demographics of IgG4-RD and its tendency to afflict middle-aged to elderly men. It is worth noting, however, that lymphoma was responsible for 19% of the malignancies in the IgG4-RD cohort, compared with only 4% in the control cohort. These data may suggest a possible interplay between the immune dysregulation found in IgG4-RD and lymphomagenesis.
Disease history of IgG4-RD seems to differ between IgG4-RD patients with malignancy and those without. IgG4-RD patients with malignancy history develop IgG4-RD at a later age and had higher serum IgG4 concentrations compared with the subgroup without malignancy. It should be noted that no cases of IgG4-RD involving the organ previously affected by cancer were reported.
Malignancy may therefore be a predisposing condition, at least in some patients. One hypothesis is that treatment of malignancy (e.g., radiation and chemotherapy) favors immune deregulation. Alternatively, there might be a common genetic predisposing background behind both malignancy and IgG4-RD. However, the fact that no IgG4-RD manifestation occurred at the site of a prior malignancy suggests that local changes deriving from the tumor itself or from its treatment are not a likely explanation. We anticipate further discussion about the potential connections between IgG4-RD and malignancies in the future.
CONCLUSION
The large increase in literature production on IgG4-RD in these past years reflects the increasing interest of scientific community about this topic. Despite the increased efforts, the exact pathophysiology standing behind this fibroinflammatory condition still remains enigmatic. Studies in the last years, highlighting a role for T-cell subpopulations, namely CD4þ CTLs and Tfh cells, as well as plasmablasts and pDCs in IgG4-RD, seem to open new vistas from which to explore further the biological processes leading to fibrosis. We anticipate increasing interest in targeted disease therapies based on emerging pathophysiological insights.
